By Connor Hart
A jury awarded Guardant Health $292.5 million in damages related to a false-advertising and unfair-competition lawsuit that the oncology company brought against rival Natera in 2021.
The decision, which includes $175.5 million in punitive damages, represents what Guardant Health on Monday called one of the largest false advertising verdicts in history.
The jury found that Austin, Texas-based Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal, the Palo Alto, Calif., company's early-stage colorectal cancer test, in favor of Natera's competing product.
Natera said it disagrees with the jury's decision and will ask the court to overturn it.
"The jury was asked to evaluate comparative advertisements that ran for a brief period in 2021 related to the performance of Guardant's Reveal test," the company said. "This case had nothing to do with the validity or utility of Signatera and certain key pieces of evidence supporting Natera's case were not included in this trial."
Signatera is Natera's competing cancer test to Reveal.
Guardant Health Chief Legal Officer John Saia celebrated the jury's decision. "Today's unanimous verdict holding Natera responsible for engaging in illegal and anticompetitive conduct represents a major victory for colorectal cancer patients who could benefit from our groundbreaking Reveal test," he said.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 25, 2024 17:45 ET (22:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。